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1ABSTRACT
Favorable outcome of alternate intra-arterial and systemic chemotherapy 
for retinoblastoma
Seung Min Hahn
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Chuhl Joo Lyu)
Intra-arterial chemotherapy (IAC) is one of the current standard 
treatment of retinoblastoma, however it cannot exclude the risk of 
occult micrometastases in the central nervous system in advanced stage 
retinoblastoma. Alternate fashion of IAC and intravenous 
chemotherapy (IVC) strategy was developed to increase the eye salvage 
rate and to reduce the metastatic risk. Between January 2012 and 
December 2014, 13 eyes of 12 patients with newly diagnosed 
retinoblastoma received alternate IAC and IVC in Yonsei Cancer 
Center. Eye salvage rate was assessed by the eye preservation time 
which was defined as the duration from the diagnosis to the time of 
enucleation. Total 13 eyes were classified according to the International 
Classification of Retinoblastoma (ICRB) as group B (n = 1), group C (n 
= 2), group D (n = 5), or group E (n = 5). IAC was performed three to 
five times for each eye, total 54 times. Five to fifteen courses of IVC 
were performed. During the median follow-up period of 30.4 months, 
overall eye salvage rate was 63.9 ± 14.7%. All patients survived. The 
treatment was tolerable without significant complications. Primary 
alternate IAC-IVC was tolerable and effective for retinoblastoma.
----------------------------------------------------------------------------------------
Key words: retinoblastoma – chemotherapy – infusions, intra-arterial
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Seung Min Hahn
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Chuhl Joo Lyu)
I. INTRODUCTION
With timely diagnosis and proper treatment, retinoblastoma has an excellent 
cure rate compared to other pediatric solid tumors. Survival rate is known to be 
as high as 95-97% in the United States and Europe, while the survival rate is 
60-80% in many developing countries and <50% in less developed countries1-3. 
In Korea, children who were diagnosed with retinoblastoma between 2001 and 
2010 showed a 5-year survival rate of 95.5%4. 
In spite of this, the treatment of retinoblastoma is constantly evolving, and the 
current goal of the treatment in developed countries is not only survival but also 
to save the eye, save the vision and minimize complications following therapy. 
These goals lead to the change in first-line treatment of retinoblastoma from 
enucleation or external beam radiotherapy (EBRT) to systemic chemotherapy 
and local treatment5. From the early 2000s, intra-arterial chemotherapy (IAC) 
has been introduced in a similar context. The concept of delivering the 
chemotherapeutic agent directly to the adjacent vessels of the tumor was 
introduced decades ago by Reese et al. and, Kiribuchi et al6,7. In Japan, several 
groups: Yamane et al. and, Suzuki et al. used the technique of selecting the 
internal carotid artery with a micro-balloon catheter in which the balloon 
occlusion was performed just distal to the ophthalmic artery and melphalan was 
3infused in 187 and 176 patients, respectively8,9. In United States, Abramson and 
Gobin first used the ophthalmic artery superselective cannulation method for 
IAC and they reported their experienced with IAC in 95 eyes of 78 patients, 
while Shields et al. analyzed 70 eyes in 67 patients, 198 sessions of IAC10-12. In 
both reports, IAC was effective in treating advanced stage retinoblastoma. In 
these studies, IAC was used not only as secondary or salvage therapy but also as
primary or solitary therapy. 
In the IAC era for eye preservation, advanced stage of retinoblastomas is 
treated with IAC for eye salvage, however the pathologic examination is not 
possible unless an enucleation is performed. For advanced stage retinoblastoma 
has risk of systemic metastasis or recurrence, We thought that IAC was 
basically local chemotherapy infusion strategy and it could not eradicate the 
micrometastatic foci in the central nervous system13,14. These aspects of IAC, 
expecially if the eyes are high-risk disease, have been discussed in other 
studies15. Moreover, unless systemic chemotherapy is delivered, eyes with 
high-risk features develop metastasis in 24%, while the metastatic rate is 4% 
with adjuvant systemic chemotherapy16. Therefore, the need for systemic 
chemotherapy should be considered for the patients with advanced stage 
retinoblastoma who were treated with IAC alone.
We have reported our experience with IAC and intravenous chemotherapy 
(IVC), combined approach for refractory retinoblastoma5. IAC was performed 
in 5 advanced stage (Reese-Ellsworth stage IV-V) patients with 14 sessions of
catheterization, all resulting in eye preservation. In this article, we tried 
alternated IAC-IVC approach for the newly diagnosed patients with 
retinoblastoma to achieve improved eye salvage rates and to assess feasibility of 
the alternate treatment.
4II. MATERIALS AND METHODS
1. Patients
Among the 40 patients who were diagnosed and treated as retinoblastoma in 
Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea between 
January 2012 and December 2014, 26 patients received IAC. Fourteen patients 
who received IAC as secondary salvage therapy were excluded, and 13 eyes of 
12 newly diagnosed patients were evaluated (1 bilateral cases). Patients’ 
demographic data including sex, age at diagnosis (months), symptoms at 
diagnosis, mutation of the RB1 gene, grouping according to the 
Reese-Ellsworth (RE) group, International Classification of Retinoblastoma 
(ICRB), brain magnetic resonance imaging (MRI) were reviewed 
retrospectively. This study was approved by the ethical committee of Yonsei 
University College of Medicine, Yonsei University Health System (approval 
number: 4-2015-0538). 
2. Treatment
All patients received both IAC and IVC. IVC consisting of vincristine 
(1.5mg/m2, day 1), carboplatin (200mg/m2, day 1-2), etoposide (150mg/m2, 
day 1-2), and cyclosporine (12mg/kg, day 1-2) (CVE) was performed as first 
choice, and it was repeated every 3 weeks. After repeating 6 to 8 courses of first 
line chemotherapy, 2nd line chemotherapy including vincristine (1.5mg/m2, day 
1), doxorubicin (45mg/m2, day 1), cyclophosphamide (500mg/m2, day 1-3) 
(VDC) have been tried to the patients who were suspected to have remained 
viable tumor after the first line therapy. The other regimen was applied to the 
patients when the disease progresses. High dose chemotherapy, including 
carboplatin (500mg/m2, day 1-3), etoposide (250mg/m2, day 4-6), and thiotepa 
(300mg/m2, day 4-6) as a conditioning regimen, with autologous hematopoietic 
5stem cell transplantation was performed in one patient.
In most cases, IAC was performed alternatively with IVC (alternate IAC-IVC). 
However, according to the availability of the IAC treatment and patients’ 
condition, systemic chemotherapy alone or IAC alone therapies were performed 
consecutively during the treatment course. Our technique of IAC has been 
described in the previous report5. Femoral arterial puncture was performed 
under general anesthesia. Four French angiocatheters were passed through the 
aorta, and carotid artery subsequently, and then the Marathon flow 
microcatheter was positioned into the ophthalmic artery during 30 minutes of 
melphalan infusion. All of the procedures were performed by a trained 
interventional radiologist. The doses of 3 mg, 4 mg or 5 mg of melphalan were 
used according to the age of the patient (< 1yr, 3 mg; 1-2 yr, 4 mg; >3 yr, 5 mg).
The complications of IAC were closely monitored for one day, and the patient 
was discharged on the next day after the procedure. All adverse events related to 
the treatments were assessed by Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.0.
Focal therapies such as thermotherapy, laser photocoagulation, cryotherapy, 
and intravitreal chemotherapy (melphalan) injection were also performed in the 
patients. The ophthalmologist meticulously examined the eye after every one or 
two courses of chemotherapy under general anesthesia and determined the need 
for focal therapy. 
3. Statistical analysis 
Data were presented as median value with range, number (n) with percent, and 
mean ± standard deviation. The duration of the eye salvage was calculated from 
the day of diagnosis to the day of enucleation. Eye salvage rate was analyzed 
using the Kaplan-Meier method, and tested by log-rank test. All statistical 
analyses were performed using the SPSS statistical software (version 20.0, 
SPSS Inc., Chicago, IL).
6III. RESULTS
Demographic characteristics of the patients are presented in Table 1. Median 
age of total 12 patients was 18.8 months at diagnosis (range, 11.0 to 35.8 
months). Two patients with eye number 5, and 6 had RB1 gene mutation. Total 
13 eyes were classified according to the RE system as group 3 (n = 3, 23.1%), 
group 4 (n = 3, 23.1%), or group 5 (n = 7, 53.8%). The ICRB classified the eyes 
as group B (n = 1, 7.7%), group C (n = 2, 15.4%), group D (n = 5, 38.5%), or 
group E (n = 5, 38.5%).
All eyes received alternate IAC-IVC. IVC was usually performed prior to 
IAC, and only three eyes (eye number 8, 10, and, 12 in Table 2) initially
received IAC followed by IVC. Most of the eyes received IVC first for one to 
five cycles (one cycle, n = 3; two cycles, n = 3; three cycles, n = 2, four cycles, 
n = 1; five cycles, n = 1), and started IAC in their later treatment course. Eye 
number 2, 4, and 5 received three or four courses of IVC ahead of IAC. In these 
patients, IVC courses were given to the patients to assess independent 
therapeutic effect of IVC rather than IAC before introducing IAC. The 
evaluation showed insufficient regression of tumor, or progression of seeding. 
Patient 3 received alternate IAC-IVC at first, meanwhile ceased IAC because of 
vitreous hemorrhage. The median duration from diagnosis to first IAC was 46 
days (range, 9 to 119 days) in all patients. The longest duration for the eye to 
receive IAC was 119 days in eye number 3-right, and in that case, five courses 
of IVC were administered before IAC due to failure of procedure to target the 
ophthalmic artery. The patient had bilateral retinoblastoma, and the other eye
received IAC after two courses of IVC. The median age of the patients at first 
IAC was 22.7 months (range, 12.5 to 36.6 months), and three to five times for 
each eye, total 54 times of IAC was performed in 13 eyes. 
Five to fifteen courses (median, 8 courses) of IVC were performed in the 
7patients (Table 2). The first-line chemotherapy with CVE was applied to all of
the patients. Four patients (5 eyes) received the other chemotherapy regimen 
consists of VDC. Only one eye (eye number 2) with multiple vitreous seeding 
received high dose chemotherapy with autologous hematopoietic stem cell 
rescue. The patient was treated before we started intraviteral chemotherapy. 
Local therapy was performed in 12 out of the 13 eyes (92.3%). Transpupillary 
thermotherapy was the most commonly performed local therapy (total 22 times). 
Intravitreal melphalan injection was administered in 5 eyes for a total 15 times. 
Besides, cryotherapy, indirect laser photocoagulation, endolaser coagulation 
were performed according to the judgement of the ophthalmologist to control 
the posteriorly located small seedings (Table 2).
Complications related to the treatments are described in Table 3. Neutropenia 
was the most common complication related to IVC. Patient 7, showed grade 2 
rashes and hypertension during cyclosporine infusion and patient 9 had grade 3 
rashes. In most patients, IAC was performed without serious side effect. 
However, three patients developed grade 2 periorbital edema, one patient 
developed vitreous hemorrhage, and patient 4, showed hypotension and 
desaturation right after the infusion of melphalan in the selected ophthalmic 
artery.
There was no death during the median follow-up duration of 30.4 months
(range, 8.5 to 43.5 months). Overall eye salvage rate was 63.9 ± 14.7% (Figure 
1). Overall eye salvage rate in group D and E (total 10 eyes) was 49.2 ± 18.8%. 
According to the group, ICRB group B, and C resulted in 100% of salvage rate, 
33.3 ± 27.2% in group D, and 60.0 ± 21.9% in group E (p=0.39) (Figure 2). 
Four out of the thirteen eyes (30.7%) were enucleated due to progression of 
vitreous and subretinal seeding in two eyes (eye number 1 and, 5), and vitreous 
hemorrhage with high intraocular pressure, and retinal detachment in two eye 
(eye number 7 and, 9). Histopathologic evaluation of the enucleated eyes 
8revealed residual tumor in three cases except the eye number 9, and eye number 
1 showed choroid involvement, hence the patient received adjuvant 
chemotherapy after enucleation. Two eyes were classified as ICRB group E, and 
two eyes were classified as ICRB group D.
9Table 1. Patients characteristics
Eye number Sex Age at diagnosis (months) Symptom at diagnosis RB1 gene mutation RE group ICRB staging
1 Male 22.2 Leukocoria No 5 D
2 Male 34.1 Leukocoria No 5 D
3-right
Male 18.8 Leukocoria No
4 C
3-left 5 E
4 Female 18.5 Leukocoria No 3 C
5 Male 18.8 Leukocoria Yes1 5 E
6 Female 18.6 Leukocoria Yes2 3 B
7 Male 27.1 Visual disturbance Not checked 5 E
8 Male 14.9 Leukocoria No 5 E
9 Female 11.0 Leukocoria No 3 D
10 Female 30.1 Leukocoria No 5 E
11 Female 29.9 Leukocoria No 4 D
12 Male 35.8 Leukocoria Not checked 4 D
1intron6 c.607+G>T. 
2exon18 c.1735C>T.
RE: Reese-Ellsworth, ICRB: Internatinal Classification of Retinoblastoma.
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Table 2. Treatment summary and outcome
Eye 
number
IAC 
times
CTx times 
before first 
IAC
CTx regimen
Number of 
courses of 
systemic 
CTx
Age at 
first IAC
(months)
First IAC 
from 
diagnosis 
(days)
Local therapy
Eye 
salvage
duration 
(months)
1 3 2 CVE, VDC 15 (12+3)1 24.0 56 ILP, cryotherapy, endolaser2 10.83
2 5 3 CVE, VDC, CTE 12 36.6 76 TTT 41.8
3-right 4 5 CVE, VDC 12 22.7 119 TTT 40.3
3-left 5 2 CVE, VDC 12 20.2 44 TTT 40.3
4 5 4 CVE 8 21.6 95 TTT 41.8
5 5 3 CVE 8 20.9 62 TTT, endolaser photocoagulation 9.63
6 3 2 CVE, VDC 9 20.5 57 TTT, Ivtr melphalan 31.3
7 3 1 CVE 6 28.3 37 TTT 7.63
8 3 0 CVE 5 15.3 13 22.8
9 3 1 CVE, VDC 11 12.5 46 Ivtr melphalan 17.33
10 5 0 CVE 7 30.6 14 Ivtr melphalan, ILP, cryotherapy  16.6
11 5 1 CVE 6 30.9 29 Ivtr melphalan 10.6
12 5 0 CVE 6 36.1 9 Ivtr melphalan 9.4
1three adjuvant cycles of chemotherapy after enucleation. 
2endolaser for cataract treatment. 
3enucleation.
IAC: Intra-arterial chemotherapy, CTx: chemotherapy, CVE: cisplatin, vincristine, etoposide with cyclosporine, TTT: transpupillary 
thermotherapy, VDC: vincristine, doxorubicin, cyclophosphamide, ILP: indirect laser photocoagulation, CTE: carboplatin, thiotepa, 
etoposide, Ivtr: intravitreal.
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Table 3. Adverse events related to treatment
Complications Grade 2 Grade 3 Grade 4
Systemic chemotherapy related
neutropenia 4 (30.8) 2 (15.4) 7 (53.8)
neutropenic fever 0 7 (53.8) 0
pneumonia 0 1 (7.7) 0
vomiting 2 (15.4) 2 (15.4) 0
rash 1 (7.7) 1 (7.7) 0
hypertension 1 (7.7) 0 0
Intra-arterial chemotherapy related
perorbital edema 3 (23.1) 0 0
vitreal hemorrhage 0 2 (15.4) 0
cardio-respiratory reflex reaction 0 0 1 (7.7)
nonspecific focal brain lesion 1 (7.7) 0 0
presented as number (%).
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Figure 1. Eye salvage rate of retinoblastoma using alternate intra-arterial and 
intravenous chemotherapy approach
1A. Overall eye salvage rate 
1B. Overall eye salvage rate per International Classification of Retinoblastoma 
group (B or C vs. D vs. E)
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IV. DISCUSSION
Alternate IAC-IVC approach showed promising result of eye preservation 
(overall eye salvage rate, 63.9 ± 14.7%). Advanced stage of retinoblastomas 
were salvaged adequately. There were no significant toxicities associated with 
IAC or IVC. Histopathologic examination of enucleated eyes showed high risk 
pathologic features in one eye, and this indicated the need for adding IVC to 
IAC.
Reese introduced intra-arterial triethylene melamine injection via the carotid 
artery with radiotherapy, and this was the first attempt at IAC for 
retinoblastoma6. After decades, in Japanese groups, selective IAC of 
retinoblastoma by temporary occlusion of the internal carotid artery was 
generally successful with respect to tolerability8,9. However, there were some 
limitations because the chemotherapeutic agents may flow into other cerebral 
arteries. Moreover, they combined multimodal approaches such as systemic 
chemotherapy, local treatment and even external beam radiotherapy, hence, the 
sole role of IAC was not evidently proved in their valuable works.
Superselective ophthalmic artery chemotherapy was introduced by Abramson 
from the Memorial Sloan Kettering Cancer Center in 200812. They avoided the 
balloon occlusion method and a technically well selected ophthalmic artery was 
used. Chemotherapeutic agents were infused over 30 minutes in a pulsatile 
fashion, and the procedure was well tolerated. Their several subsequent reports 
proved the beneficial effect of IAC in treatment of refractory or primary 
retinoblastoma treatment. Since then many institutions adopted IAC as the 
major modality for treating retinoblastoma.
We introduced alternate treatment fashion with IAC and IVC, which is 
assumed to be the best in reducing metastasis rate and increasing the eye 
salvage rate. Because IAC is one of the local chemotherapeutic infusion 
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methods, it cannot eradicate the potential metastatic foci in the brain. IAC only 
approach can impose the metastasis risk in advanced stage retinoblastoma. 
Moreover, current trend of retinoblastoma treatment is to preserve eye globes 
and eye sights, hence the exact pathologic confirmation is impossible during 
current treatment approaches. Ophthalmologic examination alone may not 
exclude all of the high risk pathologic features. We experienced no metastasis 
nor deaths from retinoblastoma with this alternative approach. The high-risk 
pathologic features are known to increase the risk of metastasis in 
retinoblastoma, and indicate the necessity of adjuvant systemic 
chemotherapy13,14,17,18. These features include anterior chamber seeding, 
choroidal involvement, tumor beyond the lamina cribrosa, intraocular 
hemorrhage, scleral and extrascleral extension, and tumor at the cut end of the 
optic nerve. Presence of these high-risk pathologic features are correlated with 
the clinical staging system of group D or E retinoblastoma. Group D 
retinoblastoma has high risk features in 17% of patients, and group E 
retinoblastoma has high risk features in 24% of patients19. In this context, all of 
the advanced ICRB stage retinoblastoma have possibility of micrometastases, 
yet it is difficult to know before we obtain the pathology by enucleation. Our 
treatment approach is unique because we tried both treatment concurrently, IAC 
for intraocular lesion and IVC for possible micrometastases. Because advanced 
stage has more risk of micrometastases, this approach may benefit more in the 
advanced stages.
We experienced no metastasis nor deaths from retinoblastoma with this 
alternative approach. However most metastasis occur several years after the last 
treatment. Hence, more data and long-term follow-up of at least ten years after 
our alternate approach are needed to prove its definite role in preventing 
metastasis and, increasing survival. 
Various complications of systemic chemotherapy including hearing 
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impairment, second malignancies, and other hematologic and, infectious 
complications in patients with retinoblastoma are well known20. Compared with 
other centers where systemic chemotherapy is performed, we have performed 
more number of courses of chemotherapy, median 8 courses5,21. Nonetheless, 
systemic chemotherapy was tolerable without severe complications, and 
neutropenia and neutropenic fever were the most common complications after 
systemic chemotherapy. 
Generally, IAC is a tolerable procedure in most patients. Local periocular 
edema and conjunctival injection can occur; however, these can be managed 
well22,23. Three of our patients also experienced eyelid edema. In recent reports, 
choroidal ischemia, intraocular vascular complications, and hyperpigmentation 
of the retinal pigment epithelium were documented but their negative effects on 
the eye survival rate and visual acuity should be followed up and evaluated 
further11,22. We did not observe vascular changes; however, close monitor is 
needed. There was no hematologic toxicity over grade 2 during IAC. The most 
serious acute complication of IAC is hemodynamic instability24. We noted this 
complication in one patient. This phenomenon is thought to be related to
increased vagal tone, and the time sequence of the event was similar to that in
the other report24. Although the patient was recovered completely, we 
discontinued IAC. One patient who had received five courses of previous IAC, 
showed T2 hyperintense lesion in the left frontal cortex incidentally on MRI; 
however she had no clinical symptoms and the lesion disappeared 
spontaneously after three months. This finding is thought to be due to a 
nonspecific focal ischemic lesion after cerebral angiography.  
Shields CL presented their experience in the chemotherapy era, and they 
showed that ICRB group D patients had an eye salvage rate of 47%25. With 
systemic chemotherapy combined with local therapy or radiotherapy, only 
25~38% of eyes in high RE stage patients could be salvaged in other articles26,27. 
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However, recent reports of IAC show an eye-opening progress. Gobin and 
Abramson reported their 4 year experience of treating 95 eyes in 78 patients10. 
They used melphalan and added topotecan, carboplatin, or methotrexate 
depending upon the retinoblastoma stage and the status of the eye. Even in the 
RE group V eyes, the naïve eyes were preserved at a rate of 70%. None of the 
12 eyes of the RE group I~IV were enucleated20. Shields CL reported their 
5-year experience at Wills Eye Hospital, 100% eye preservation rate in ICRB 
stage B and, C patients, 94% in stage D and 36% in group E patients11. In our 
study, the salvage rate was 63.9% among all eyes. Even in the group D or E 
patients, we could preserve the eyes in 49.2%. This success rate is comparable
with that in work performed at other institutions’10,11,22,23. Instead of combining
of 2 or 3 drugs during IAC, we reduced the IAC interval after systemic 
chemotherapy from 3 weeks to 2 weeks to intensify the treatment, and this 
effect on eye preservation should be studied further. In this aspect, for treating 
advanced stage retinoblastoma, we can have two options in performing IAC; 
one option is increasing the dose intensity and the other option is adding more 
drugs.
There are limitations to this study: most patients followed the protocol of 
alternate IAC-IVC regimen; however, the time of starting IAC after diagnosis 
and the number of courses of systemic chemotherapy before and after IAC were 
varied among patients. This makes difficult to evaluate the treatment response 
and, efficacy of IAC or IVC separately. And, from September 2013, intraviteral 
chemotherapy has been introduced to the patients, however, the application of 
new treatment method was not considered. Several data were collected 
retrospectively, and this might have caused a bias. A larger number of patients 
are needed to indicate a more reliable role of combination therapy, and longer 
follow-up duration is needed to determine the long-term effect of this regimen.
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V. CONCLUSION
In conclusion, in spite of several limitations, primary IAC combined with 
systemic chemotherapy was tolerable and effective in patients with 
retinoblastoma. Combined alternative IAC and systemic chemotherapy is a 
promising option for advanced stage retinoblastoma.
18
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ABSTRACT (IN KOREAN)
망막모세포종 환자를 대상으로 한
동맥 항암 및 전신 항암 병용 요법의 효과
<지도교수    유 철 주>
연세대학교 대학원 의학과
성    명 한승민
눈동맥 항암은 망막모세포종의 표준치료로 자리 잡아가고
있으나 전신 전이나 재발을 막는데에 얼마나 효과적인지에
대해서는 아직 확립 되지않았다. 따라서 전신 항암치료와
눈동맥 항암을 병용하는 요법의 장점이 있을 것으로 생각되고
있다. 2012년 1월부터 2014년 12월까지 연세대학교 의과대학
세브란스 병원에서 망막모세포종으로 진단된 환자 중 눈동맥
항암, 전신 항암 병용요법을 시행한 12명 (13안구)을
대상으로 치료의 효과를 분석하였다. International 
Classification of Retinoblastoma (ICRB) 분류에 따라 그룹 B
(n = 1), 그룹 C (n = 2), 그룹 D (n = 5), 혹은 그룹 E (n = 5)
환자를 나누었으며 눈 적출까지 안구의 생존율을 비교하였다. 
중간 값 30.4 개월 간의 추적 관찰 기간 동안 안구의
생존율은 63.9 ± 14.7% 였으며 사망한 환자 및 심각한
부작용을 보인 환자는 없었다. 눈동맥 항암 및 전신 항암의
병용 요법이 망막모세포종의 효과적인 치료적 방법 중 하나가
될 수 있을 것으로 생각한다.
----------------------------------------------------------------------------------------
핵심되는 말: 망막모세포종, 항암 치료, 동맥 내 주입
